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In adaptation to rising stimulant strength, innate monocytes can be dynamically 
programed to preferentially express either pro- or anti-inflammatory mediators. Such 
dynamic innate adaptation or programing may bear profound relevance in host health 
and disease. However, molecular mechanisms that govern innate adaptation to 
varying strength of stimulants are not well understood. Using lipopolysaccharide (LPS), 
the model stimulant of toll-like-receptor 4 (TLR4), we reported that the expressions 
of pro-inflammatory mediators are preferentially sustained in monocytes adapted 
by lower doses of LPS, and suppressed/tolerized in monocytes adapted by higher 
doses of LPS. Mechanistically, monocytes adapted by super-low dose LPS exhibited 
higher levels of transcription factor, interferon regulatory factor 5 (IRF5), and reduced 
levels of transcriptional modulator B lymphocyte-induced maturation protein-1 
(Blimp-1). Intriguingly, the inflammatory monocyte adaptation by super-low dose LPS 
is dependent upon TRAM/TRIF but not MyD88. Similar to LPS, we also observed 
biphasic inflammatory adaptation and tolerance in monocytes challenged with varying 
dosages of TLR7 agonist. In sharp contrast, rising doses of TLR3 agonist preferentially 
caused inflammatory adaptation without inducing tolerance. At the molecular level, the 
differential regulation of IRF5 and Blimp-1 coincides with unique monocyte adaptation 
dynamics by TLR4/7 and TLR3 agonists. Our study provides novel clue toward the 
understanding of monocyte adaptation and memory toward distinct TLR ligands.
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inTrODUcTiOn
Emerging studies suggest that innate leukocytes may adopt “rudimentary” memory states depend-
ing on challenge history and strength, as reflected in the priming and tolerance paradigm of 
monocytes challenged with varying dosages of bacterial endotoxin lipopolysaccharide (LPS) (1). 
LPS is a membrane component of common mucosa gram-negative bacteria. Upon leakage into 
host systemic circulation, higher dosages of LPS may elicit a strong, yet, transient inflammatory 
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cytokine storm followed by suppression of inflammation and 
tolerance (2). Both the dramatic upswing of inflammatory 
cytokines as well as the late-phase refractory tolerance con-
tribute to severe morbidity and mortality associated with sepsis 
(3). In sharp contrast, subclinical leakage of super-low dose 
LPS may occur in humans with chronic low-grade inflamma-
tory disease (4, 5). Monocytes with prolonged adaptation to 
super-low dose LPS fail to develop tolerance and give rise to 
a non-resolving low-grade inflammatory phenotype conducive 
for chronic inflammatory disease (6). However, differential 
monocyte adaptations to challenges by other microbial products 
have not been well studied.
Upon microbial challenges, toll-like-receptors (TLRs) 
modulate complex plethora of signaling molecules that eventu-
ally activate both transcriptional activators and suppressors of 
inflammatory mediators. Of particular significance, interferon 
regulatory factor 5 (IRF5) has been a recognized master tran-
scription factor of pro-inflammatory monocytes and was shown 
to induce expression of pro-inflammatory genes, such as IL-12 
and IL-23, in both murine and human inflammatory monocytes 
(7). On the other hand, B lymphocyte-induced maturation pro-
tein-1 (Blimp-1) has been reported to be a critical transcriptional 
repressor of inflammatory genes. Blimp-1 may also be involved 
in the induction of anti-inflammatory mediators (8). In addition, 
Blimp-1 is essential for modulating homeostasis of NK cell (9), 
T cell (10), and dendritic cell (11). Blimp-1 also contributes to 
the homeostatic regulation of bone (12) and intestinal tissues 
(13). However, the modulations of IRF5 and Blimp-1 by varying 
dosage of LPS and their connection to monocyte adaptation have 
not been well examined.
Emerging data and computational analyses suggest that the 
potential competition among multiple signaling pathways within 
monocytes may be responsible for the dynamic adaptation of 
monocytes (14). In the context of TLR signaling processes, 
there are at least two potentially competitive pathways, namely 
MyD88-dependent and MyD88-independent pathways (15). 
MyD88 is a critical adaptor molecule that directs signaling traf-
fic within innate monocytes. Other key adaptors include TRIF 
and TRAM (16). Previous studies suggest that MyD88 and TRIF 
were involved in high dose LPS induced endotoxin tolerance 
effects (17). However, little is known about the roles of other 
adaptor molecules, especially TRAM, which was shown to be 
pro-inflammatory and pro-atherogenic during the pathogenesis 
of atherosclerosis (18).
To fill the critical void in this intriguing area of innate 
monocyte adaptation and memory, we examined the differential 
adaptation of monocytes by varying dosages of LPS and potential 
underlying mechanisms. We characterized the expression profiles 
of selected pro- and anti-inflammatory mediators in murine 
monocytes challenged with varying dosages of LPS as well as 
TLR3/7 agonists. The dynamic expression profiles of inflamma-
tory mediators were cross-examined with key transcriptional 
modulators such as IRF5 and Blimp-1. The potential involvement 
of MyD88 and TRAM/TRIF during the dynamic adaptation of 
monocytes were studied by employing primary bone marrow 
monocytes (BMM) collected from wild-type (WT), MyD88−/−, 
TRIF−/−, and TRAM−/− mice.
resUlTs
Monocytes adapted to higher Dose lPs 
exhibit inflammatory Tolerance While 
Preferentially express homeostatic 
Mediators. in contrast, Monocytes 
adapted to super-low Dose lPs 
Develop a low-grade inflammatory 
Profile without the expression of 
homeostatic Mediators
Although the phenomena of endotoxin tolerance and prim-
ing triggered by a short period of single dose LPS challenge 
have been well documented (19–21), limited studies are 
performed to characterize the adaptation effects of prolonged 
LPS exposures on monocytes. In this context, we assessed the 
gene expression profiles of murine monocytes continuously 
challenged with varying dosages of LPS for a 5-day period. 
We checked the cell viability among treated cells and observed 
similar cell survival among 5-day cultures of cells challenged 
varying dosages of LPS (Figure S1 in Supplementary Material). 
We also checked the cell surface expression of CD11b, a key 
marker for monocytes, and observed that >99% of living cells 
cultured by M-CSF for the 5-day period are CD11b positive 
(Figure S2 in Supplementary Material). As shown in Figure 1, 
monocytes were adapted into an anti-inflammatory “tolerant” 
phenotype after a prolonged challenge with higher dose LPS 
(1 μg/ml), as reflected in a significant reduction of selected pro-
inflammatory genes such as IL-12 and CCR5 (Figures  1A,B), 
resembling the phenotype of endotoxin tolerance. Higher 
dose LPS-adapted monocytes become potent producers of 
homeostatic genes involved in tissue repair such as ARG1 and 
iNOS (Figures 1C,D). In sharp contrast, monocytes challenged 
with super-low dose LPS (100 pg/ml) were adapted to express 
significantly higher levels of inflammatory mediators (IL-12 
and CCR5) as compared to either non-adapted monocytes or 
high dose LPS-adapted monocytes (Figures 1A,B; Figure S3 in 
Supplementary Material). We confirmed the protein levels of 
selected targets such as IL-12 and CCR5 through flow analyses 
(Figure  2). The super-low dose LPS-adapted monocytes did 
not express homeostatic tissue-repair genes ARG1 or iNOS. 
These data reveal distinct adaptation of monocytes into either 
a non-resolving inflammatory state or resolving tolerant state, 
dependent upon the relative signal strengths of prolonged LPS 
challenges.
The signature transcription factor of inflammatory monocyte 
IRF5 is induced in monocytes adapted by super-low dose LPS, 
and drastically reduced in monocytes adapted by higher dose 
LPS. On the other hand, the transcriptional modulator Blimp-1 
is reduced in monocytes adapted by super-low dose LPS and 
elevated in higher dose LPS-adapted monocytes.
Interferon regulatory factor 5 is a key signature transcription 
factor within inflammatory monocytes (7, 22), while Blimp-1 
serves as an important homeostatic modulator in myeloid 
cells (23). Elevation of IRF5 or reduction of Blimp-1 were 
associated with the pathogenesis of chronic inflammatory 
FigUre 1 | Differential priming and tolerance by Tlr agonists. Total RNA was isolated from monocytes treated with different dosages of LPS for 5 days. 
Real-time PCR was performed to determine the expression levels of CCR5 (a), IL-12 (B), ARG1 (c), and iNOS (D). Data are representative of three separate 
experiments (error bar represent SEM, **p < 0.01, ***p < 0.001, ****p < 0.0005, as compared to non-treated control group, Student’s t-test).
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diseases (8, 24, 25). Together with other transcriptional activa-
tors, IRF5 activates the expression of inflammatory mediators. 
On the other hand, Blimp-1 may serve as an anti-inflammatory 
mediator through competing and inhibiting target sequences of 
IRFs (26). To determine the molecular mechanisms responsible 
for the dynamic adaptation of monocytes, we examined the 
cellular levels of IRF5 and Blimp-1. Consistent with the tolerant 
phenotype, monocytes adapted with higher dose LPS (1 μg/ml) 
had markedly reduced levels of IRF5 and restored Blimp-1 
levels as compared to control monocytes (Figure 3A). In sharp 
contrast, the non-resolving inflammatory monocytes adapted 
with 100 pg/ml LPS had elevated levels of IRF5 and reduced 
levels of Blimp-1 (Figure 3A).
The reduction of inflammatory suppressor Blimp-1 may 
allow for the development of non-resolving inflammatory 
monocyte. We further tested whether reduced gene expres-
sion or protein stability may account for Blimp-1 reduction 
in non-resolving inflammatory monocytes. As shown in 
Figure  3B, the mRNA levels of PRDM1, the gene encoding 
Blimp-1, were not altered comparing control monocytes and 
monocytes adapted by 100  pg/ml LPS. This suggests that 
Blimp-1 reduction in adapted inflammatory monocytes may 
be caused by reduced protein stability. To confirm this, we 
applied proteasome inhibitor MG-132. As shown in Figure 3C, 
application of MG-132 abolished the reduction of Blimp-1 
in monocytes adapted by lower dose LPS. The degradation 
of Blimp-1 has not been studied in monocytes, although a 
previous report suggested that TNF receptor-associated factor 
2 (TRAF2)-mediated JNK activation may be critically involved 
in Blimp-1 downregulation in B cells (27). Previous reports 
revealed that TRAF2 overexpression was correlated with 
upregulated expression of inflammatory genes (28, 29). In 
addition, TRAF2 also plays central role in signaling pathway 
induced by ER stress (30, 31). Thus, we further tested the levels 
of TRAF2 in differentially adapted monocytes. We observed 
that TRAF2 levels were induced in non-resolving inflammatory 
monocytes adapted by super-low dose LPS (Figure  3A). In 
contrast, TRAF2 levels returned to resting levels in tolerant 
monocytes adapted by 1 μg/ml LPS (Figure  3A).
To further provide causative proof with regard to the role of 
IRF5 in the programing of monocytes, we performed siRNA 
analyses to selectively decrease the levels of IRF5. We observed 
that selective knockdown of IRF5 led to the abolishment of CCR5 
induction by super-low dose LPS (Figure 4).
The non-resolving inflammatory 
Monocyte adaptation is independent of 
MyD88, but Dependent on TraM and TriF
Next, we tested the roles of TLR adaptor molecules during the 
dynamic adaptation of monocytes. Bone marrow monocytes 
from MyD88−/− and TRIF−/− mice were adapted for 5 days with 
super-low and higher dosages of LPS. As shown in Figures 5A,B, 
the induction of inflammatory mediators, such as IL-12 and 
CCR5, was not affected by MyD88 deficiency, suggesting that 
MyD88 is not involved in the inflammatory adaptation of 
monocytes. In contrast, the induction of inflammatory IL-12 
and CCR5 was abolished in TRIF or TRAM-deficient monocytes 
FigUre 2 | Differential modulation of ccr5 and il-12 protein levels by lPs. Differentially challenged cells were immunostained with specific antibodies 
against either CCR5 or IL-12, and cellular protein levels of CCR5 and IL-12 were monitored by flow cytometry. Error bar represents SEM of three experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001, as compared to non-treated control group, Student’s t-test.
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(Figures 5E,F,I,J). On the other hand, the homeostatic monocyte 
adaptation to higher dose LPS as reflected in the expression of 
ARG1 was dependent upon MyD88, but not TRIF or TRAM 
(Figures  5C,G,K). TRIF or TRAM deletion did not affect the 
induction of iNOS by higher dose LPS (Figures 5D,H,L). Our 
data further support the emerging concept that the adaptation 
processes of monocytes are highly dynamic, complex, and may 
differentially involve unique signaling pathways. In terms of the 
non-resolving inflammatory monocyte adaptation, TRAM and 
TRIF, instead of MyD88 are critically required.
Downstream of TRAM/TRIF, we further tested whether 
TRAM or TRIF may be involved in the activation of IRF5, TRAF2, 
and reduction of Blimp-1 in monocytes adapted by super-low 
dose LPS. As shown in Figure  6A, the induction of TRAF2, 
IRF5, and the reduction of Blimp-1 in inflammatory monocytes 
adapted by super-low dose LPS (100  pg/ml) were abolished in 
TRAM-deficient BMDM. On the other hand, MyD88-deficient 
BMM adapted by 100 pg/ml LPS experienced similar induction 
of TRAF2, IRF5, and reduction of Blimp-1 as compared to WT 
BMM (Figure 6B). Compared with WT monocytes, the induction 
of TRAF2 in TRIF-deficient monocytes was attenuated. Taken 
together, our data suggest that the non-resolving inflammatory 
adaptation of monocytes to super-low dose LPS is not MyD88 
dependent, and dependent on TRAM/TRIF pathway. Our results 
are consistent with previous findings of pro-inflammatory role of 
TRAM/TRIF in the chronic pathogenesis of atherosclerosis (18).
FigUre 3 | Differential regulation of irF5 and PrDM1 by different dosages of lPs. Monocytes were treated with different dosages of LPS w/o MG132 as 
indicated, total RNA was isolated for RT-PCR (B), and whole cell lysates were obtained for western blot. Proteins were separated on SDS-PAGE and levels of 
Blimp-1, IRF5, TRAF2, and β-actin were detected (a,c). Data are representative of three separate experiments. Error bars represent SEM of three experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001, as compared to non-treated control group, Student’s t-test.
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Tlr7 agonist induces Both inflammatory 
and Tolerant adaptation of Monocyte, 
While Tlr3 agonist selectively induces 
inflammatory adaptation without inducing 
Monocyte Tolerance
Toll-like receptor 4 is unique among TLRs for its usage of both 
MyD88 and TRAM/TRIF-dependent pathways. Other TLRs 
may preferentially use one of these pathways. This led us to 
explore whether the inflammatory adaptation of monocytes is 
limited to TLR4 and LPS signaling pathway or may be similarly 
programed by other TLR agonists. To this regard, we specifically 
tested the effects of TLR3 and TLR7 agonists, given the fact that 
TLR3 selectively uses TRIF-dependent pathway and that TLR7 
may use both the MyD88 and TRAM pathways (16, 32). Indeed, 
monocytes adapted by varying dosages of TLR7 agonist CL264 
FigUre 4 | selective knockdown of irF5 abolishes the induction ccr5 by super-low dose lPs monocytes co-cultured with either control or 
irF5-specific sirnas were challenged with lPs. The levels of CCR5 were measured by flow cytometry. Error bar represents SEM of three experiments. 
**p < 0.01, ***p < 0.001, as compared to non-treated control group, Student’s t-test.
6
Yuan et al. Dynamic Adaptation of Innate Monocyte Programing
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 497
exhibited similar dynamics as compared to monocytes adapted 
by LPS. Monocytes with prolonged challenges with lower dose 
of TLR7 agonist CL264 (100 nM) were selectively adapted into 
an inflammatory state with elevated expressions of IL-12 and 
CCR5, and no expression of Arg1 and iNOS (Figures 7A–D). In 
contrast, monocytes adapted with higher dose CL264 (100 nM, 
1  μM) were tolerant with reduced expression of IL-12 and 
CCR5, and elevated induction of homeostatic genes such as 
ARG1 and iNOS.
In terms of the molecular mechanisms, we observed partially 
similar patterns of IRF5 and Blimp-1 modulation by CL-264 
as compared to LPS. Lower-dose CL-264 induced IRF5 and 
reduced Blimp-1. In contrast, although failed to reduce IRF5 
level, higher dose CL-264 restored Blimp-1 in adapted mono-
cytes (Figure 7E).
In contrast to TLR7/4 agonists, monocytes failed to develop 
tolerant adaptation when challenged with TLR3 agonist Poly 
I:C (Figure 8). The expression of pro-inflammatory mediators, 
IL-12 and CCR5, kept rising with increasing amount of Poly I:C 
challenges, and ARG1 was not induced by higher dosages of Poly 
I:C (Figures  8A–C). At the mechanistic level, the inductions 
of IRF5 and TRAF2 were unabated by rising concentrations 
of Poly I:C (Figure 8E). Rising concentrations of Poly I:C also 
led to a persistent reduction of Blimp-1 without restoration as 
compared to adapted monocytes by higher dose of LPS challenge 
(Figure 8E). Taken together, our data reveal that TLR7 agonist 
induces similar inflammatory monocyte adaptation and toler-
ance, as elicited by LPS. In contrast, TLR3 agonist preferentially 
induces inflammatory adaptation without tolerance.
DiscUssiOn
Our data collected from this study offer novel insight with regard 
to the adaptation dynamics of innate monocytes. We observed 
that TLR4 agonist LPS may adapt monocytes into either a non-
resolving inflammatory state or a tolerance anti-inflammatory 
state depending upon LPS signal strength. Prolonged monocyte 
adaptation to higher dosages of LPS led to reduced expression 
FigUre 5 | The non-resolving inflammatory monocyte adaptation is independent of MyD88, but dependent on TraM and TriF. (a–l) Total RNAs were 
harvested from LPS-treated monocytes with MyD88, TRIF, and TRAM deficiency. Real-time PCR was performed to determine the expression levels of CCR5 
(a,e,l), IL-12 (B,F,J), ARG1 (c,g,K), and iNOS (D,h,l). Data are representative of three separate experiments (error bar represent SEM, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001, as compared to non-treated control group, Student’s t-test).
7
Yuan et al. Dynamic Adaptation of Innate Monocyte Programing
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 497
of pro-inflammatory mediators such as IL-12 and CCR5, and 
elevated expression of anti-inflammatory mediators such as 
ARG1 and iNOS. In contrast, prolonged adaptation to super-
low dose LPS gave rise to an opposite phenotype with elevated 
expression of IL-12/CCR5. Lower dose LPS may favor the 
inflammatory monocyte adaptation via the activation of IRF5 
and reduction of Blimp-1 through TRAM/TRIF, instead of 
MyD88, mediated pathway. Resembling TLR4, TLR7 agonist 
may similarly modulate the dynamic monocyte adaptation, with 
lower dosages of CL264 inducing, while higher dosages of CL264 
FigUre 6 | Differential modulation of irF5 and Blimp-1. Whole cell 
lysates were harvested from LPS-treated monocytes with MyD88, TRIF, and 
TRAM deficiency. Protein levels of Blimp-1, IRF5, TRAF2, and β-actin were 
detected (a,B). Data are representative of three separate experiments.
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reducing the expression of inflammatory mediators IL-12/CCR5. 
On the other hand, TLR3 agonist Poly I:C exhibited uniphasic 
adaptation of pro-inflammatory monocytes. Together, our data 
demonstrated the potential presence of competing circuitries 
that can fine tune monocyte memory dynamics in adaptation to 
varying TLR signal strength.
Monocyte adaptation reflects a unique facet of the emerg-
ing innate memory concept (21, 33). Previous attempts at 
defining innate memory have largely limited to the leukocyte 
phenotypic modifications due to challenges with distinct 
stimulants, as reflected in the distinct macrophage phenotypes 
programed by either IFN-γ or IL-4 (34). Limited attention has 
been given to signal strength-dependent programing on innate 
leukocytes. Reports from us and others indicated that LPS can 
dose-dependently induce either monocyte/macrophage priming 
or tolerance to a subsequent higher dose LPS challenge (6, 21, 
35). This current study expands these previous findings and 
demonstrates that prolonged stimulation of innate monocyte 
with lower-dose LPS drives an inflammatory phenotype, while 
prolonged stimulation with higher-dose LPS causes an anti-
inflammatory adaptation. We further demonstrate that IRF5 is a 
critical transcription factor involved in the enhanced expression 
of IL-12 and CCR5 in programed monocytes by super-low dose 
LPS. We further observed that monocytes may differentially 
adapt to prolonged challenges of unique TLR agonists such as 
TLR7 and TLR3 agonists. Our data may bear significant con-
ceptual and translational implications. In contrast to the simple 
paradigm of one signal accounting for one phenotype that is a 
far-cry from the complex dynamics of monocyte memory, our 
data reveal dynamic adaptation of innate monocytes dependent 
upon not only the chemical nature of corresponding stimulant 
but also the signal strength and history of stimulation. In line 
with our finding, a recent report demonstrates opposing effects 
of acute and chronic administration of TGF-β on immune cell 
activation (36). Our current study provides a conceptual clue, 
which warrants future systems analyses of complex dynamics of 
monocyte adaptation.
At the mechanistic level, our data clarify an important issue 
with regard to the differential usages of MyD88 and TRAM/TRIF 
pathways during monocyte adaptation and memory. Although 
initial studies with cell lines and overexpression analyses sug-
gested that MyD88 may account for the inflammatory signaling 
processes downstream of TLR4 (37), in vivo analyses with MyD88 
knockout mice suggested a much more complex scenario (38, 
39). With the chronic atherosclerosis model, TRAM, or TRIF 
deficiency, instead of MyD88 deficiency, was found to have 
reduced inflammation and atherosclerosis progression (18). 
Recent molecular analyses reveal that MyD88 pathway not only 
induces NF-κB activation but also multiple negative feedback 
loops that cause tolerant adaptation (40, 41). In contrast, our cur-
rent study was the first report revealing TRAM/TRIF path as the 
key circuit involved in the low-grade inflammatory adaptation of 
monocytes. Instead of inducing negative feedback modulators, 
our data suggest that TRAM/TRIF pathway may be responsible 
for the removal of negative modulators such as Blimp-1, thus 
disallowing the development of anti-inflammatory tolerance and 
favoring the inflammatory monocyte adaptation.
Our observation with regard to inflammatory and anti-
inflammatory adaptation of monocytes to distinct TLR agonists 
with varying stimulant strength may hold potential translational 
values in therapies against chronic disease. For example, anti-
inflammatory monocyte adaptation by higher TLR7 agonist 
may hold potential value in the treatment of chronic inflam-
matory disease such as atherosclerosis. Re-enforcing this 
consideration, a previous animal study with TLR7 agonist has 
shown promise in alleviating the progression of atherosclerotic 
plaques (42). It is intriguing to note that TLR3 agonist fails 
to illicit anti-inflammatory monocyte adaptation, potentially 
due to its sole usage of TRIF pathway instead of the MyD88 
pathway. This is in consistent with some previous reports that 
demonstrated the lack of tolerance in monocytes/macrophages 
treated with TLR3 agonist. For example, a previous study with 
RAW264.7 cells revealed that the pretreatment with Poly I:C 
led to increased IL-12 production following a subsequent LPS 
stimulation (43, 44). At the translational level, low-grade inflam-
matory monocyte adaptation by TLR3 agonist may serve as a 
potential strategy to boost immune surveillance of tumor. Our 
work also re-enforces the significance of carefully considering 
the effects of drug dosages in the prevention and treatment of 
chronic inflammatory diseases.
Our current study has addressed a focused mechanism 
regarding the programing of monocytes. Future studies are 
clearly needed to systematically address the wider and complex 
signaling networks involved in the dynamic programing of 
monocytes. In addition to the differential usage of adaptors 
and transcription factors, distinct configurations of cellular 
receptors and/or co-receptors may also play a significant role. 
We have indeed observed that the levels of TLR4 and CD14 
FigUre 7 | Differential regulation of monocytes responses by Tlr7 ligand cl264. Total RNA was isolated from monocytes treated with different dosages of 
CL264 for 5 days. Real-time PCR was performed to determine the expression levels of CCR5 (a), IL-12 (B), ARG1 (c), and iNOS (D). Protein levels of Blimp-1, 
IRF5, and β-actin were determinate by western blot (e). Data are representative of three separate experiments (error bar represent SEM, *p < 0.05, ***p < 0.001, 
****p < 0.0001, as compared to non-treated control group, Student’s t-test).
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may vary in cells challenged with varying dosages of LPS 
(Figure  S4 in Supplementary Material). In addition, other 
cellular mediators (either soluble or cell-membrane bound) 
produced through the training program may exert autocrine 
effects for the differential programing. However, our prolonged 
culture study may mimic the in vivo situation where persistent 
TLR agonists may exit and contribute to inflammatory polari-
zation. Our phenotypic observations with regard to priming 
and tolerance also are consistent with previous studies with 
short-time LPS exposures (17, 21, 35, 41). Furthermore, our 
study also complements previous studies with human mono-
cytes with prolonged training (33). Extensive future studies are 
warranted to perform fine-mapping of monocyte phenotypes in 
adaptation to diverse TLR agonists and antagonists, in order to 
harness the full potential of monocyte memory in the treatment 
and prevention of human disease.
MaTerials anD MeThODs
animals
C57BL/6 were maintained and bred under standard pathogen-free 
conditions. MyD88−/− and TRIF−/− mice were kindly provided by 
Dr. Michael Fessler at National Institute of Environmental Health 
Sciences. TRAM−/− mice were generously provided by Dr. Holger 
Eltzschig at University of Colorado. 8- to 12-week-old male mice 
were used for the experiments. All animal experiments were 
approved, prior to the initiation of this study, by the Institutional 
Animal Care and Use Committee (IACUC) of Virginia Polytechnic 
Institute and State University.
reagents
Lipopolysaccharide (Escherichia coli 0111:B4) was purchased 
from Sigma. CL264 and Poly I:C were purchased from InvivoGen. 
FigUre 8 | Differential regulation of monocytes responses by Tlr3 ligand Poly i:c. Total RNA was isolated from monocytes treated with different dosages 
of Poly I:C for 5 days. Real-time PCR was performed to determine the expression levels of CCR5 (a), IL-12 (B), ARG1 (c), and iNOS (D). Protein levels of Blimp-1, 
IRF5, TRAF2, and β-actin were determinate by western blot (e). Data are representative of three separate experiments (error bar represent SEM, ****p < 0.0001, as 
compared to non-treated control group, Student’s t-test).
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Murine macrophage colony-stimulating factor (M-CSF) was 
obtained from PeproTech. Anti-Blimp-1 antibody, anti-IRF5, 
anti-TRAF2 antibodies were obtained from cell signaling tech-
nology. Anti-β-actin antibody was obtained from Santa Cruz.
Protein extraction and analyses
Cells were washed with cold PBS after specified treatments and 
harvested in SDS lysis buffer containing protease and phosphatase 
inhibitors as previously described (21, 44). Protein concentration 
was assessed by Bradford assay. Following SDS-PAGE, protein 
bands were transferred to an immunoblot PVDF membrane 
(Bio-Rad) and subjected to immunoblot analysis with indicated 
antibodies. Intensity of each band was quantified using the Multi 
Gage software (Fujifilm).
real-time rT-Pcr analyses
Total RNA was extracted using TRIzol (Thermo Fisher Scientific), 
according to the manufacturer’s protocol. RNA was reverse-
transcribed using the high-capacity cDNA reverse transcription 
kit (Thermo Fisher Scientific). Real-time PCR was performed on 
a Bio-Rad CFX96 machine using SYBR Green mix (Bio-Rad). 
The relative levels of different transcripts were calculated using 
the ΔΔCt method, and results were normalized based on the 
expression of β-actin.
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In Vitro culture of Murine Monocytes
Crude BM cells isolated from C57 BL/6 mice were cultured in 
RPMI 1640 medium (Sigma-Aldrich) supplemented with 10% 
FBS (HyClone), 2 mM l-glutamine, 1% penicillin/streptomycin 
(Thermo Fisher Scientific), and with M-CSF (10 ng ml−1) in the 
presence of different doses of LPS (from 100 to 1 μg ml−1). Fresh 
LPS and M-CSF was added to the cell cultures every 2 days. After 
5 days, cells were harvested.
Flow cytometry analyses
Murine BM cells were cultured in the presence of M-CSF and 
different doses of LPS as described above. In some experiments, 
control or IRF5 siRNA (30  pmol, Life Technologies) was also 
added to cell cultures. After 5  days, cells were harvested and 
stained with anti-CD11b, anti-Ly6C, anti-Ly6G, anti-CCR5, anti-
TLR4, and anti-CD14 antibodies (BioLegend). Propidium iodide 
(PI) was also added to determine the cell viability. To detect the 
production of IL-12, BM cells cultured for 5 days were treated 
with PMA (20 ng/ml), ionomycin (1 μg/ml), and GolgiStopTM 
protein transport inhibitor (BD Biosciences) for 4 h, and then 
stained with anti-Ly6C, anti-Ly6G, and anti-CD11b antibodies. 
After fixation and permeabilization using Cytofix/CytopermTM 
kit (BD Biosciences), cells were stained with anti-IL-12 antibody 
(BD Biosciences). The cell phenotype was then analyzed by flow 
cytometer. The data were processed by FACSDiva or Flow Jo.
statistical analysis
Statistical analyses were performed using Prism Version 5 
software (GraphPad). Significance of difference was analyzed 
with a Student’s t-test. When more than two groups were com-
pared, one-way ANOVA was performed. Data were presented 
as means  ±  SEM. p values less than 0.05 were considered 
significant.
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